Page last updated: 2024-11-04

pyrazinoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pyrazinoic acid: active metabolite of pyrazinamide; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pyrazine-2-carboxylic acid : The parent compound of the class of pyrazinecarboxylic acids, that is pyrazine bearing a single carboxy substituent. The active metabolite of the antitubercular drug pyrazinamide. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1047
CHEMBL ID613
CHEBI ID71311
SCHEMBL ID23757
MeSH IDM0046746

Synonyms (70)

Synonym
VGL ,
MLS000069596 ,
smr000059041
2-pyrazinecarboxylic
nsc-27192
nsc27192
AB-131/40186434
98-97-5
pyrazine-2-carboxylic acid
nsc-13146
2-pyrazine carboxylic acid
2-pyrazinoic acid
piazinecarboxylic acid
pyrazinic acid
nsc13146
paradiazinecarboxylic acid
2-pyrazinecarboxylic acid
pyrazinoic acid
pyrazinemonocarboxylic acid
pyrazinecarboxylic acid
pyrazinecarboxylic acid, 99%
AC-2442
CHEMBL613 ,
chebi:71311 ,
bdbm50216541
pyrazinoicacid
inchi=1/c5h4n2o2/c8-5(9)4-3-6-1-2-7-4/h1-3h,(h,8,9)
nipzzxufjpqhnh-uhfffaoysa-
P0940
STK802305
AKOS000119670
pyrazine-2-carboxylicacid
C19915
HMS2234J12
einecs 202-718-1
unii-2wb23298sp
2wb23298sp ,
nsc 13146
FT-0631518
PS-3389
AM20070429
PB27363
2-carboxypyrazine
CX1040
HMS3371F05
pyrazinoic acid [mi]
BP-30070
CS-M0892
SCHEMBL23757
pyrazine 2-carboxylic acid
pyrazine-carboxylic acid
pyrazine carboxylic acid
pyrazoic acid
STR06281
Q-101891
2-pyrazinecarboxylicacid
OPERA_ID_935
mfcd00006130
F2191-0112
pyrazinecarboxylic acid, purum, >=98.0% (t)
DTXSID30243367
pyrazine-2-carboxylic acid; pyrazinamide imp. a (ep); pyrazinamide impurity a
SY001166
pyrazin-2-carboxylic acid
2-pyrazinic acid
Q7263414
EN300-19900
2- carboxylic acid pyrazine
HY-76353
Z104476002

Research Excerpts

Overview

Pyrazinoic acid (POA) is a metabolite of the anti-tuberculosis drug pyrazinamide (PZA) Its detection can be used to assess the resistance of Mycobacterium tuberculosis in cultures. Only sensitive strains of the bacteria can metabolize PZA into POA.

ExcerptReferenceRelevance
"Pyrazinoic acid (POA) is a metabolite of the anti-tuberculosis drug pyrazinamide (PZA), and its detection can be used to assess the resistance of Mycobacterium tuberculosis in cultures, as only sensitive strains of the bacteria can metabolize PZA into POA. "( Prussian blue (PB) modified gold nanoparticles as a SERS-based sensing platform for capturing and detection of pyrazinoic acid (POA).
Cialla-May, D; Jiménez-Avalos, G; Liu, C; Popp, J; Sheen, P; Zhang, WS; Zimic, M, 2024
)
3.1

Pharmacokinetics

The main pharmacokinetic parameters of pyrazinamide and pyrazinoïc acid (its major metabolite) were determined after oral administration of 1,500 mg/d in 10 patients with normal renal function. The developed population Pharmacokinetic model adequately described the disposition of Pyrazinamide and Pyrazinoic acid and can be useful for dose determination in patients with MDR-TB.

ExcerptReferenceRelevance
"The main pharmacokinetic parameters of pyrazinamide and pyrazinoïc acid (its major metabolite) were determined after oral administration of 1,500 mg/d in 10 patients with normal renal function and of 1,000 mg/d in 10 patients with impaired renal function (renal insufficiency)."( [Pharmacokinetic study of pyrazinamide and pyrazinoic acid in subjects with normal renal function and patients with renal failure].
Chambraud, E; Fredj, G; Thuillier, A; Vayre, P,
)
0.39
"The plasma and urine pharmacokinetic parameters of pyrazinamide and of its metabolites (pyrazinoic acid, 5-hydroxy-pyrazinamide, 5-hydroxy-pyrazinoic acid and pyrazinuric acid) have been studied after a single oral dose of pyrazinamide 27 mg."( Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects.
Duwoos, H; Guyonnaud, C; Hoang, TP; Lacroix, C; Lafont, O; Laine, G; Nouveau, J, 1989
)
0.5
" Nonlinear mixed-effects modelling using Monolix 2018R1 software was employed to estimate population pharmacokinetic parameters."( Population Pharmacokinetic Modelling of Pyrazinamide and Pyrazinoic Acid in Patients with Multi-Drug Resistant Tuberculosis.
Mugabo, P; Mulubwa, M, 2019
)
0.76
"The developed population pharmacokinetic model adequately described the disposition of pyrazinamide and pyrazinoic acid and can be useful for dose determination of pyrazinamide in patients with MDR-TB."( Population Pharmacokinetic Modelling of Pyrazinamide and Pyrazinoic Acid in Patients with Multi-Drug Resistant Tuberculosis.
Mugabo, P; Mulubwa, M, 2019
)
0.97
" In a previous study, the compounds were evaluated and showed moderate antimycobacterial activity and no important cytotoxic profile; however, information about their pharmacokinetic profile is lacking."( Assessment of the Physicochemical Properties and Stability for Pharmacokinetic Prediction of Pyrazinoic Acid Derivatives.
Campos, ML; Corrêa, MF; de Queiroz Aranha, CMS; DeGrandis, RA; Fernandes, JPS; Franchin, TB; Peccinini, RG; Ulian Silva, BC, 2020
)
0.78

Bioavailability

ExcerptReferenceRelevance
" Bioavailability of pyrazinamide was only slightly increased in patients, its dialysis extraction coefficient being 55."( Pyrazinamide and pyrazinoic acid pharmacokinetics in patients with chronic renal failure.
Farinotti, R; Fessi, H; Kenouch, S; Méry, JP; Montes, C; Stamatakis, G; Trouvin, JH, 1988
)
0.61
" The method was applied to assess the comparative bioavailability of a 500mg PZA test and reference formulation in healthy subjects."( An improved LC-MS/MS method for the simultaneous determination of pyrazinamide, pyrazinoic acid and 5-hydroxy pyrazinoic acid in human plasma for a pharmacokinetic study.
Sanyal, M; Shah, JV; Shah, PA; Sharma, P; Shrivastav, PS, 2016
)
0.66

Dosage Studied

ExcerptRelevanceReference
" This could be completely blocked by combination dosing with allopurinol, an inhibitor of xanthine oxidase."( Hyperuricemia induced by the uricosuric drug probenecid in rats.
Shinosaki, T; Yonetani, Y, 1991
)
0.28
" Under these conditions, we found a clear dose-response correlation, proving that POA does have specific antimicrobial activity."( Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?
Flory, MA; Heifets, LB; Lindholm-Levy, PJ, 1989
)
0.79
" This study shows that, with these dosage regimens, almost all the pharmacokinetic parameters are identical for pyrazinamide and pyrazinoic acid in patients with normal renal function and patients with impaired renal function."( [Pharmacokinetic study of pyrazinamide and pyrazinoic acid in subjects with normal renal function and patients with renal failure].
Chambraud, E; Fredj, G; Thuillier, A; Vayre, P,
)
0.6
" These data may lead to recommendations of a reduction in the dosage of pyrazinamide in dialysis patients."( Pyrazinamide and pyrazinoic acid pharmacokinetics in patients with chronic renal failure.
Farinotti, R; Fessi, H; Kenouch, S; Méry, JP; Montes, C; Stamatakis, G; Trouvin, JH, 1988
)
0.61
" The paradoxical effect observed with probenecid was not seen in the E3040 dose-response curve for the uric acid excretion rate."( Mechanism of the uricosuric action of E3040, a drug used to treat inflammatory bowel disease II: study using DBA/2N mice.
Furitsu, H; Iga, T; Kotaki, H; Sawada, Y; Yamada, H, 1999
)
0.3
"46 μm, as measured by inertial impaction, for POA-leu and POA-NH4, respectively) and with properties (stoichiometric 1:1 ratio of salt to drug, melting points at ∼180 °C, with water content of <1%) that would support further development as an inhaled dosage form."( Spray Dried Aerosol Particles of Pyrazinoic Acid Salts for Tuberculosis Therapy. [Corrected].
Dhillon, J; Durham, PG; Fourie, PB; German, N; Hickey, AJ; Mitchison, DA; Mortensen, N; Zhang, Y, 2015
)
0.7
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
drug metabolitenull
antitubercular agentA substance that kills or slows the growth of Mycobacterium tuberculosis and is used in the treatment of tuberculosis.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pyrazinecarboxylic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency17.74070.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency25.11890.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.62280.177814.390939.8107AID2147
thioredoxin reductaseRattus norvegicus (Norway rat)Potency89.12510.100020.879379.4328AID588453
phosphopantetheinyl transferaseBacillus subtilisPotency15.84890.141337.9142100.0000AID1490
USP1 protein, partialHomo sapiens (human)Potency35.48130.031637.5844354.8130AID743255
Smad3Homo sapiens (human)Potency0.56230.00527.809829.0929AID588855
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency44.66840.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency8.91250.035520.977089.1251AID504332
chromobox protein homolog 1Homo sapiens (human)Potency31.62280.006026.168889.1251AID540317
gemininHomo sapiens (human)Potency6.51310.004611.374133.4983AID624296
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency100.00006.309660.2008112.2020AID720709
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nicotinate phosphoribosyltransferaseHomo sapiens (human)Ki0.00010.00000.00060.0019AID1618606
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hydroxycarboxylic acid receptor 2Homo sapiens (human)EC50 (µMol)6.30000.00871.20176.3096AID308653
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (75)

Processvia Protein(s)Taxonomy
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
response to oxidative stressNicotinate phosphoribosyltransferaseHomo sapiens (human)
NAD salvageNicotinate phosphoribosyltransferaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
base-excision repairNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
double-strand break repairNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
chromatin remodelingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein deacetylationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of cell population proliferationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
determination of adult lifespanNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
response to UVNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
retrotransposon silencingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of double-strand break repair via homologous recombinationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of lipid metabolic processNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
pericentric heterochromatin formationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
subtelomeric heterochromatin formationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein destabilizationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of insulin secretionNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of telomere maintenanceNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
circadian regulation of gene expressionNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of transcription elongation by RNA polymerase IINAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
ketone biosynthetic processNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of protein import into nucleusNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
glucose homeostasisNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of circadian rhythmNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
post-translational protein modificationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of fat cell differentiationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of gluconeogenesisNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of gene expression, epigeneticNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of glycolytic processNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of glucose importNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of protein export from nucleusNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of fibroblast proliferationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of protein secretionNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of lipid catabolic processNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein delipidationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
cardiac muscle cell differentiationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of cold-induced thermogenesisNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of protein localization to chromatinNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of protein localization to chromatinNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
DNA repair-dependent chromatin remodelingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of stem cell population maintenanceNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of chondrocyte proliferationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of protein localization to plasma membraneNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of blood vessel branchingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein localization to site of double-strand breakNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of stem cell proliferationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of stem cell differentiationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of cellular senescenceNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of double-strand break repairNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
neutrophil apoptotic processHydroxycarboxylic acid receptor 2Homo sapiens (human)
positive regulation of neutrophil apoptotic processHydroxycarboxylic acid receptor 2Homo sapiens (human)
negative regulation of lipid catabolic processHydroxycarboxylic acid receptor 2Homo sapiens (human)
positive regulation of adiponectin secretionHydroxycarboxylic acid receptor 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayHydroxycarboxylic acid receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (30)

Processvia Protein(s)Taxonomy
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
nicotinate phosphoribosyltransferase activityNicotinate phosphoribosyltransferaseHomo sapiens (human)
protein bindingNicotinate phosphoribosyltransferaseHomo sapiens (human)
transferase activityNicotinate phosphoribosyltransferaseHomo sapiens (human)
metal ion bindingNicotinate phosphoribosyltransferaseHomo sapiens (human)
chromatin bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
damaged DNA bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
zinc ion bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nucleotidyltransferase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent histone deacetylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
chromatin DNA bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nucleosome bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein homodimerization activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent histone H3K9 deacetylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD+ bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent histone H3K18 deacetylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD+-protein-arginine ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
DNA damage sensor activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent histone H3K56 deacetylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent protein demyristoylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent protein depalmitoylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD+- protein-lysine ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
TORC2 complex bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
transcription corepressor activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nicotinic acid receptor activityHydroxycarboxylic acid receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular regionNicotinate phosphoribosyltransferaseHomo sapiens (human)
cytosolNicotinate phosphoribosyltransferaseHomo sapiens (human)
azurophil granule lumenNicotinate phosphoribosyltransferaseHomo sapiens (human)
extracellular exosomeNicotinate phosphoribosyltransferaseHomo sapiens (human)
cytosolNicotinate phosphoribosyltransferaseHomo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
pericentric heterochromatinNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
endoplasmic reticulumNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
site of double-strand breakNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
site of DNA damageNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nucleoplasmNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
intracellular membrane-bounded organelleNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
chromosome, subtelomeric regionNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
chromatinNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
plasma membraneHydroxycarboxylic acid receptor 2Homo sapiens (human)
cell junctionHydroxycarboxylic acid receptor 2Homo sapiens (human)
plasma membraneHydroxycarboxylic acid receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (64)

Assay IDTitleYearJournalArticle
AID1802837Fluorimetric Assay from Article 10.1002/cbic.201600655: \\Studies of the Binding of Modest Modulators of the Human Enzyme, Sirtuin 6, by STD NMR.\\2017Chembiochem : a European journal of chemical biology, 05-18, Volume: 18, Issue:10
Studies of the Binding of Modest Modulators of the Human Enzyme, Sirtuin 6, by STD NMR.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID102219Minimum inhibitory concentration against MAC NJ211 using Middlebrook 7H9 with glycerol and OADC enrichment2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives.
AID143845Minimum Inhibitory Concentration in clinical isolates against Mycobacterium avium complex 1011995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity.
AID278999Inhibition of fatty acid synthase 1 in Mycobacterium bovis BCG assessed as incorporation of [1-14C]acetate in C16 biosynthesis at 1500 ug/ml at pH 6.02007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.
AID279000Inhibition of fatty acid synthase 1 in Mycobacterium bovis BCG assessed as incorporation of [1-14C]acetate in C16 biosynthesis at 1500 ug/ml at pH 6.82007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.
AID144288In vitro inhibitory activity against Mycobacterium kansasii (strain type-SWK) at pH 6.61992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Antimycobacterial activity of a series of pyrazinoic acid esters.
AID278998Inhibition of fatty acid synthase 1 in Mycobacterium tuberculosis assessed as incorporation of [1-14C]acetate in C16 biosynthesis at 1250 ug/ml at pH 6.02007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.
AID143417In vitro inhibitory activity against Mycobacterium tuberculosis (strain type-H37Rv) at pH 6.61992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Antimycobacterial activity of a series of pyrazinoic acid esters.
AID406065Inhibition of Mycobacterium tuberculosis fatty acid synthase 1 expressed in Mycobacterium smegmatis mc2 2700 assessed as NADPH oxidation by spectrophotometry2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.
AID143285In vitro inhibitory activity against Mycobacterium tuberculosis (strain type-BUR) at pH 5.81992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Antimycobacterial activity of a series of pyrazinoic acid esters.
AID1848088Antimycobacterial activity against POA-resistant Mycobacterium bovis BCG harboring PanD Leu132Arg mutant assessed as inhibition of bacterial growth incubated for 5 days by broth microdilution method2022Bioorganic & medicinal chemistry, 11-15, Volume: 74Structure activity relationship of pyrazinoic acid analogs as potential antimycobacterial agents.
AID1737596Binding affinity to Mycobacterium tuberculosis RpsA C-terminal domain (285 to 476 residues) assessed as quenching rate constant by fluorescence quenching titration based analysis2020European journal of medicinal chemistry, Jun-15, Volume: 196Discovery and evaluation of new compounds targeting ribosomal protein S1 in antibiotic-resistant Mycobacterium Tuberculosis.
AID1737594Binding affinity to Mycobacterium tuberculosis RpsA C-terminal domain (285 to 476 residues) assessed as dissociation constant by fluorescence quenching titration based analysis2020European journal of medicinal chemistry, Jun-15, Volume: 196Discovery and evaluation of new compounds targeting ribosomal protein S1 in antibiotic-resistant Mycobacterium Tuberculosis.
AID143271In vitro inhibitory activity against Mycobacterium tuberculosis (strain type-ATCC 35828) at pH 6.61992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Antimycobacterial activity of a series of pyrazinoic acid esters.
AID406204Inhibition of Mycobacterium tuberculosis fatty acid synthase 1 expressed in Mycobacterium smegmatis mc2 2700 assessed as [2-14C]]malonyl-CoA incorporation into fatty acid at 6000 uM2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.
AID145155Minimum Inhibitory Concentration against Mycobacterium tuberculosis ATCC 358011995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity.
AID144160Minimum Inhibitory Concentration against clinical isolates of Mycobacterium kansasii S1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity.
AID406203Inhibition of Mycobacterium tuberculosis fatty acid synthase 1 expressed in Mycobacterium smegmatis mc2 2700 assessed as [2-14C]]malonyl-CoA incorporation into fatty acid at 3000 uM2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.
AID1848090Binding affinity to Mycobacterium tuberculosis PanD assessed as change in enthalpy by isothermal titration calorimetry2022Bioorganic & medicinal chemistry, 11-15, Volume: 74Structure activity relationship of pyrazinoic acid analogs as potential antimycobacterial agents.
AID494411Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by microplate Alamar blue assay2010European journal of medicinal chemistry, Aug, Volume: 45, Issue:8
Synthesis and anti-mycobacterial evaluation of some pyrazine-2-carboxylic acid hydrazide derivatives.
AID1848086Antimycobacterial activity against Mycobacterium bovis BCG Pasteur ATCC35734 assessed as inhibition of bacterial growth incubated for 5 days by broth microdilution method2022Bioorganic & medicinal chemistry, 11-15, Volume: 74Structure activity relationship of pyrazinoic acid analogs as potential antimycobacterial agents.
AID138703Minimum inhibitory concentration against Mtb H37Ra using Middlebrook 7H9 with glycerol and OADC enrichment2002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives.
AID1494470Inhibition of Rickettsia prowazekii N-terminal His6-tagged methionine aminopeptidase 1 expressed in Escherichia coli DLB3 Rosetta cells at 10 uM using Met-AMC as substrate preincubated for 1 hr followed by 30 mins incubation after substrate addition measu2018Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8
The identification of inhibitory compounds of Rickettsia prowazekii methionine aminopeptidase for antibacterial applications.
AID143284In vitro inhibitory activity against Mycobacterium tuberculosis (strain type-BUR) at pH 6.61992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Antimycobacterial activity of a series of pyrazinoic acid esters.
AID627944Binding affinity to Mycobacterium tuberculosis fatty acid synthase 1 at 8 mM by STD NMR spectrophotometric assay2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Pyrazinamide, but not pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis fatty acid synthase I.
AID143272In vitro inhibitory activity against Mycobacterium tuberculosis (strain type-ATCC 35828) at pH 5.81992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Antimycobacterial activity of a series of pyrazinoic acid esters.
AID1605095Inhibition of N-terminal His6-sumo-tagged full length Staphylococcus aureus ClpP expressed in Escherichia coli BL2 (DE3) at 10 uM pre-incubated for 10 mins before Suc-LY-AMC addition and measured after 1 hr by fluorescence based assay relative to control2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Discovery of Novel Peptidomimetic Boronate ClpP Inhibitors with Noncanonical Enzyme Mechanism as Potent Virulence Blockers
AID144002In vitro inhibitory activity against Mycobacterium tuberculosis (strain type-ATCC 27289) at pH 5.8.1992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Antimycobacterial activity of a series of pyrazinoic acid esters.
AID1848091Binding affinity to Mycobacterium tuberculosis PanD assessed as change in entropy by isothermal titration calorimetry2022Bioorganic & medicinal chemistry, 11-15, Volume: 74Structure activity relationship of pyrazinoic acid analogs as potential antimycobacterial agents.
AID145157Minimum Inhibitory Concentration against Mycobacterium tuberculosis ATCC 35828 PZA resistant form1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity.
AID278995Antimicrobial activity against Mycobacterium tuberculosis at pH 6 by broth microdilution test2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.
AID584545Dissociation constant, pKa of the compound2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
AID278996Antimicrobial activity against Mycobacterium tuberculosis at pH 6.8 by broth microdilution test2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.
AID143418In vitro inhibitory activity against Mycobacterium tuberculosis (strain type-H37Rv) at pH 5.81992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Antimycobacterial activity of a series of pyrazinoic acid esters.
AID1848089Binding affinity to Mycobacterium tuberculosis PanD assessed as dissociation constant by isothermal titration calorimetry2022Bioorganic & medicinal chemistry, 11-15, Volume: 74Structure activity relationship of pyrazinoic acid analogs as potential antimycobacterial agents.
AID308653Agonist activity at human cloned GPR109a receptor by forskolin-stimulated cAMP production test2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Agonist lead identification for the high affinity niacin receptor GPR109a.
AID144289In vitro inhibitory activity against Mycobacterium kansasii (strain type-SWK) at pH 5.81992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Antimycobacterial activity of a series of pyrazinoic acid esters.
AID145154Minimum Inhibitory Concentration against Mycobacterium tuberculosis ATCC 272941995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity.
AID278997Inhibition of fatty acid synthase 1 in Mycobacterium tuberculosis assessed as incorporation of [1-14C]acetate in C16 biosynthesis at 250 ug/ml at pH 5.52007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.
AID144004In vitro inhibitory activity against Mycobacterium tuberculosis (strain type-ATCC 27289). at pH 6.61992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Antimycobacterial activity of a series of pyrazinoic acid esters.
AID143846Minimum Inhibitory Concentration in clinical isolates against Mycobacterium avium complex ATCC 496011995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (176)

TimeframeStudies, This Drug (%)All Drugs %
pre-199048 (27.27)18.7374
1990's25 (14.20)18.2507
2000's34 (19.32)29.6817
2010's53 (30.11)24.3611
2020's16 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.10 (24.57)
Research Supply Index5.21 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.55%)5.53%
Reviews3 (1.65%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other178 (97.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]